The prostate cancer treatment market, valued at USD 14.01 billion in 2024 and projected to reach USD 31.60 billion by 2034 at a CAGR of 8.5%, is undergoing a structural transformation driven by segment-specific advancements in drug development, radiation modalities, and surgical interventions. Market segmentation reveals distinct performance patterns across therapy types—hormonal...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek